Genome-Wide Profiling of Prognostic Alternative Splicing Pattern in Pancreatic Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2019 Sep 26

PMID 31552163

Citations 23

Authors

Min Yu

Weifeng Hong

Shiye Ruan

Renguo Guan

Lei Tu

Bowen Huang

Baohua Hou

Zhixiang Jian

Liheng Ma

Haosheng Jin

Affiliations

Soon will be listed here.

Abstract

Alternative splicing (AS) has a critical role in tumor progression and prognosis. Our study aimed to investigate pancreatic cancer-specific AS events using RNA-seq data, gaining systematic insights into potential prognostic predictors. We downloaded 10,623 genes with 45,313 pancreatic cancer-specific AS events from the Cancer Genome Atlas (TCGA) and SpliceSeq database. Cox univariate analyses of overall survival suggested there was a remarkable association between 6,711 AS events and overall survival in pancreatic cancer patients ( < 0.05). The area under the curves (AUC) of the receiver operator characteristic curves (ROC) of risk score was 0.89 for final prognostic predictor. Results indicated that AS events of DAZAP1, RBM4, ESRP1, QKI, and SF1 were significantly associated with overall survival. The results of FunRich showed that transcription factors KLF7, GABPA, and SP1 were the most highly related to survival-associated AS genes. Furthermore, using DriverDBv2, we identified 13 driver genes associated with survival-associated AS events, including TP53 and CDC27. Thus, we concluded that the aberrant AS patterns in pancreatic cancer patients might serve as prognostic predictors.

Citing Articles

RNA-binding protein DAZAP1 accelerates the advancement of pancreatic cancer by inhibiting ferroptosis.

Wang X, Fan H, Ye X, Hu Y, Xiao Y, Zhang M Eur J Med Res. 2025; 30(1):3.

PMID: 39754243 PMC: 11699656. DOI: 10.1186/s40001-024-02261-0.

The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.

Huang M, Qin S, Gao H, Kim W, Xie F, Yin P Cells. 2024; 13(19.

PMID: 39404386 PMC: 11475995. DOI: 10.3390/cells13191622.

Exploring Splicing Modulation as an Innovative Approach to Combat Pancreatic Cancer: SF3B1 Emerges as a Prognostic Indicator and Therapeutic Target.

Sciarrillo R, Terrana F, Comandatore A, Supadmanaba I, Wang B, Hassouni B Int J Biol Sci. 2024; 20(8):3173-3184.

PMID: 38904016 PMC: 11186358. DOI: 10.7150/ijbs.92671.

The Many Roads from Alternative Splicing to Cancer: Molecular Mechanisms Involving Driver Genes.

Gimeno-Valiente F, Lopez-Rodas G, Castillo J, Franco L Cancers (Basel). 2024; 16(11).

PMID: 38893242 PMC: 11171328. DOI: 10.3390/cancers16112123.

RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing.

Maurin M, Ranjouri M, Megino-Luque C, Newberg J, Du D, Martin K Nat Commun. 2023; 14(1):8444.

PMID: 38114498 PMC: 10730836. DOI: 10.1038/s41467-023-44126-w.

References

Sue N, Jack B, Eaton S, Pearson R, Funnell A, Turner J . Targeted disruption of the basic Krüppel-like factor gene (Klf3) reveals a role in adipogenesis. Mol Cell Biol. 2008; 28(12):3967-78. PMC: 2423134. DOI: 10.1128/MCB.01942-07. View

Wang E, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C . Alternative isoform regulation in human tissue transcriptomes. Nature. 2008; 456(7221):470-6. PMC: 2593745. DOI: 10.1038/nature07509. View

Dong J, Chen C . Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci. 2009; 66(16):2691-706. PMC: 11115749. DOI: 10.1007/s00018-009-0045-z. View

Warzecha C, Shen S, Xing Y, Carstens R . The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol. 2009; 6(5):546-62. PMC: 2823379. DOI: 10.4161/rna.6.5.9606. View

Wei D, Wang L, Kanai M, Jia Z, Le X, Li Q . KLF4α up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer. Gastroenterology. 2010; 139(6):2135-45. PMC: 3245983. DOI: 10.1053/j.gastro.2010.08.022. View

Shields M, Dangi-Garimella S, Krantz S, Bentrem D, Munshi H . Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem. 2011; 286(12):10495-504. PMC: 3060503. DOI: 10.1074/jbc.M110.195628. View

Arafat H, Lazar M, Salem K, Chipitsyna G, Gong Q, Pan T . Tumor-specific expression and alternative splicing of the COL6A3 gene in pancreatic cancer. Surgery. 2011; 150(2):306-15. PMC: 3163121. DOI: 10.1016/j.surg.2011.05.011. View

Piva F, Giulietti M, Burini A, Principato G . SpliceAid 2: a database of human splicing factors expression data and RNA target motifs. Hum Mutat. 2011; 33(1):81-5. DOI: 10.1002/humu.21609. View

Guillaudeau A, Durand K, Rabinovitch-Chable H, Pommepuy I, Mesturoux L, Robert S . Adult diffuse gliomas produce mRNA transcripts encoding EGFR isoforms lacking a tyrosine kinase domain. Int J Oncol. 2011; 40(4):1142-52. PMC: 3680776. DOI: 10.3892/ijo.2011.1287. View

10.

Di Modugno F, Iapicca P, Boudreau A, Mottolese M, Terrenato I, Perracchio L . Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proc Natl Acad Sci U S A. 2012; 109(47):19280-5. PMC: 3511125. DOI: 10.1073/pnas.1214394109. View

11.

Shin S, Kim S, Hong S, Kim Y, Song K, Park K . Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas. 2013; 42(2):216-22. DOI: 10.1097/MPA.0b013e31825b6ab0. View

12.

Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y . Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg. 2013; 258(2):336-46. DOI: 10.1097/SLA.0b013e3182827a65. View

13.

Unruh D, Turner K, Srinivasan R, Kocaturk B, Qi X, Chu Z . Alternatively spliced tissue factor contributes to tumor spread and activation of coagulation in pancreatic ductal adenocarcinoma. Int J Cancer. 2013; 134(1):9-20. PMC: 4122306. DOI: 10.1002/ijc.28327. View

14.

Ueda J, Matsuda Y, Yamahatsu K, Uchida E, Naito Z, Korc M . Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases. Oncogene. 2013; 33(36):4485-95. PMC: 4041859. DOI: 10.1038/onc.2013.392. View

15.

Tsai J, Yang J . Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013; 27(20):2192-206. PMC: 3814640. DOI: 10.1101/gad.225334.113. View

16.

Surget S, Khoury M, Bourdon J . Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 2014; 7:57-68. PMC: 3872270. DOI: 10.2147/OTT.S53876. View

17.

Duan W, Ma J, Ma Q, Xu Q, Lei J, Han L . The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer. Curr Cancer Drug Targets. 2014; 14(5):446-57. DOI: 10.2174/1568009614666140402105101. View

18.

Padfield E, Ellis H, Kurian K . Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma. Front Oncol. 2015; 5:5. PMC: 4310282. DOI: 10.3389/fonc.2015.00005. View

19.

Tomczak K, Czerwinska P, Wiznerowicz M . The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015; 19(1A):A68-77. PMC: 4322527. DOI: 10.5114/wo.2014.47136. View

20.

Bittoni A, Piva F, Santoni M, Andrikou K, Conti A, Loretelli C . KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma. Future Oncol. 2015; 11(13):1905-17. DOI: 10.2217/fon.15.98. View